Nadezhda S. Beresneva

Nadezhda S. Beresneva

Auto-generated profile, based on publicly available information

Nadezhda S. Beresneva

Ural State Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Russian Ophthalmological Journal
Verified
Journal Article
Open access
PDF file
EBE. V. Bobykin
E. V. Bobykin
OMO. V. Morozova
O. V. Morozova
NBN. S. Beresneva
N. S. Beresneva
Macular diseases are traditionally a serious issue in ophthalmology, which has great social impact due to widespread occurrence and significant vision loss, often irreversible. Over the past few decades, the possibilities for the diagnosis and treatment of pathologies of the retina and choroid have been significantly expanded. Randomized clinical trials provided ophthalmologists with valuable information on the natural course and treatment strategies of common retinal diseases from the viewpoint of evidence-based medicine. However, due to the large number of trials conducted, it is often difficult to make an adequate choice of data to be used in daily practice. In this review, we systematize the most valuable randomized clinical trials. To this end, we selected 42 randomized clinical studies conducted between 1979 and 2019 and focused on the treatment of age-related macular degeneration (AREDS 1, AREDS 2, ANCHOR, MARINA, PrONTO, CATT, IVAN, VIEW 1, VIEW 2, EVEREST II, PLANET, SEVEN-UP, ALTAIR, HAWK, HARRIER), choroidal neovascularization of multiple etiology (myopic, post-inflammatory, angioid-streak-related, etc. — RADIANCE, REPAIR, MYRROR, MINERVA), diabetic eye lesions (diabetic retinopathy and diabetic macular edema — ETDRS, DRCR.net Protocols B, I, S and T, RISE, RIDE, VIVID-DME, VISTA-DME, MEAD, FAME), retinal vein occlusions (BVOS, CVOS, SCORE-CRVO, SCORE-BRVO, BRAVO, CRUISE, GALILEO, COPERNICUS, VIBRANT), as well as retinopathy of prematurity (CRYO-ROP, ETROP, RAINBOW). The review summarizes the main results of these studies, which confirm the effectiveness and safety of such treatment methods as antiVEGF and photodynamic therapy, retinal laser photocoagulation, cryotherapy, corticosteroids and nutraceuticals from the viewpoint of evidence-based medicine. For greater clarity, we provide a table summarizing information on each of the randomized clinical trials considered.

15 December 2020 in Ophthalmology Reports
Verified
Journal Article
Open access
PDF file
EBEvgeny V. Bobykin
Evgeny V. Bobykin
VKVadim Ya. Krokhalev
Vadim Ya. Krokhalev
NBNadezhda S. Beresneva
Nadezhda S. Beresneva
RBRuslan V. Buslaev
Ruslan V. Buslaev
OMOlga V. Morozova
Olga V. Morozova
Background.Anti-VEGF therapy is currently regarded as the gold standard for the treatment of many macular diseases, while the results of its application in real clinical practice are often inferior to those from randomized clinical trials. Materials and methods.A study group was formed on the basis of a retrospective analysis of the medical data of patients who received anti-VEGF therapy with ranibizumab and/or aflibercept according to registered indications, and who discontinued their follow-up in the clinic (n= 214). A phone survey of patients concerning the reasons for loss to follow-up with a statistical analysis of the obtained data was carried out. Results.The majority of patients (81.3%) discontinued observation in the clinic within two years from the start of therapy (the median duration of treatment was 7 (3; 18) months). Patients with all considered diseases had an increase in best corrected visual acuity during treatment (p 0.000001), which confirms the high efficiency of the method. According to the results of the phone survey, the following categories of respondents were identified: complete cessation of treatment 120 (56.1%) patients, change of clinic 20 (9.3%), death 23 (10.7%), status not established 51 (23.8%). The most frequent reasons for stopping treatment were dissatisfaction with its results (59 cases; 49.2%), financial burden (49; 40.8%), and systemic comorbidities (24; 20.0%). Conclusion.Searching approaches to increase patients treatment adherence is one of the priorities for improving anti-VEGF therapy.